Long-Term Outcomes From a Prospective Trial of Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer

Published:February 07, 2011DOI:


      Hypofractionated radiotherapy has an intrinsically different normal tissue and tumor radiobiology. The results of a prospective trial of stereotactic body radiotherapy (SBRT) for prostate cancer with long-term patient-reported toxicity and tumor control rates are presented.

      Methods and Materials

      From 2003 through 2009, 67 patients with clinically localized low-risk prostate cancer were enrolled. Treatment consisted of 36.25 Gy in 5 fractions using SBRT with the CyberKnife as the delivery technology. No patient received hormone therapy. Patient self-reported bladder and rectal toxicities were graded on the Radiation Therapy Oncology Group scale (RTOG).


      Median follow-up was 2.7 years. There were no grade 4 toxicities. Radiation Therapy Oncology Group Grade 3, 2, and 1 bladder toxicities were seen in 3% (2 patients), 5% (3 patients), and 23% (13 patients) respectively. Dysuria exacerbated by urologic instrumentation accounted for both patients with Grade 3 toxicity. Urinary incontinence, complete obstruction, or persistent hematuria was not observed. Rectal Grade 3, 2, and 1 toxicities were seen in 0, 2% (1 patient), and 12.5% (7 patients), respectively. Persistent rectal bleeding was not observed. Low-grade toxicities were substantially less frequent with QOD vs. QD dose regimen (p = 0.001 for gastrointestinal and p = 0.007 for genitourinary). There were two prostate-specific antigen (PSA), biopsy-proven failures with negative metastatic workup. Median PSA at follow-up was 0.5 ± 0.72 ng/mL. The 4-year Kaplan-Meier PSA relapse-free survival was 94% (95% confidence interval, 85%–102%).


      Significant late bladder and rectal toxicities from SBRT for prostate cancer are infrequent. PSA relapse-free survival compares favorably with other definitive treatments. The current evidence supports consideration of stereotactic body radiotherapy among the therapeutic options for localized prostate cancer.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Dasu A.
        Is the α/β value for prostate tumours low enough to be safely used in clinical trials?.
        Clin Oncol. 2007; 19: 289-301
        • Fowler J.F.
        • Ritter M.A.
        • Chappell R.J.
        • Brenner D.J.
        What hypofractionated protocols should be tested for prostate cancer?.
        Int J Radiat Oncol Biol Phys. 2003; 56: 1093-1104
        • Yeoh E.E.
        • Holloway R.H.
        • Fraser R.J.
        • et al.
        Hypofractionated vs. conventionally fractionated radiation therapy for prostate carcinoma: Updated results of a Phase III randomized trial.
        Int J Radiat Oncol Biol Phys. 2006; 66: 1072-1083
        • Lukka H.
        • Hayter C.
        • Julian J.A.
        • et al.
        Randomized trial comparing two fractionation schedules for patients with localized prostate cancer.
        J Clin Oncol. 2005; 23: 6132-6138
        • Kupelian P.A.
        • Willoughby T.R.
        • Reddy C.A.
        • et al.
        Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience.
        Int J Radiat Oncol Biol Phys. 2007; 68: 1424-1430
        • Livsey J.E.
        • Cowan R.A.
        • Wylie J.P.
        • et al.
        Hypofractionated conformal radiotherapy in carcinoma of the prostate: Five-year outcome analysis.
        Int J Radiat Oncol Biol Phys. 2003; 57: 1254-1259
        • Lloyd-Davies R.W.
        • Collins C.D.
        • Swan A.V.
        Carcinoma of prostate treated by radical external beam radiotherapy using hypofractionation. Twenty-two years’ experience (1962–1984).
        Urology. 1990; 36: 107-111
      1. Yoshioka Y, Konishi K, Sumida I, et al. Monotherapeutic high-dose-rate brachytherapy for prostate cancer: Five-year results of an extreme hypofractionation regimen with 54 gy in nine fractions. Int J Radiat Oncol Biol Phys. In press.

        • Martinez A.A.
        • Demanes J.
        • Vargas C.
        • et al.
        High-dose-rate prostate brachytherapy: An excellent accelerated-hypofractionated treatment for favorable prostate cancer.
        Am J Clin Oncol. 2010; 33: 481-488
        • Madsen B.L.
        • Hsi R.A.
        • Pham H.T.
        • et al.
        Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized prostate disease: First clinical trial results.
        Int J Radiat Oncol Biol Phys. 2007; 67: 1099-1105
        • King C.R.
        • Brooks J.D.
        • Gill H.
        • et al.
        Stereotactic body radiotherapy for localized cancer: Interim results of a prospective Phase II clinical trial.
        Int J Radiat Oncol Biol Phys. 2009; 73: 1043-1048
        • Katz A.J.
        • Santoro M.
        • Ashley R.
        • et al.
        Stereotactic body radiotherapy for organ-confined prostate cancer.
        BMC Urol. 2010; 10: 1
      2. Townsend NC, Huth BJ, Ding W, et al. Acute toxicity after CyberKnife-delivered hypofractionated radiotherapy for treatment of prostate cancer. Am J Clin Oncol. In press.

        • Greene F.L.
        • Page D.L.
        • Flemming I.D.
        • et al.
        AJCC Manual for staging cancer.
        6th ed. Springer Verlag, New York2002 (p. 309–313)
      3. Common toxicity criteria (Version 2.0).
        National Institutes of Health, Bethesda, MD1998
        • Peeters S.T.H.
        • Heemsbergen W.D.
        • Koper P.C.M.
        • et al.
        Dose–Response in radiotherapy for localized prostate cancer: Results of the Dutch Multicenter Randomized Phase III Trial comparing 68 Gy of radiotherapy with 78 Gy.
        J Clin Oncol. 2006; 24: 1990-1996
        • Kuban D.A.
        • Tucker S.L.
        • Dong L.
        • et al.
        Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer.
        Int J Radiat Oncol Biol Phys. 2008; 70: 67-74
        • Zietman A.L.
        • Bae K.
        • Slater J.D.
        • et al.
        Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09.
        J Clin Oncol. 2010; 28: 1106-1111
        • Dearnley D.P.
        • Sydes M.R.
        • Graham J.D.
        • et al.
        Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First RESULTS from the MRC RT01 Randomized Controlled Trial.
        Lancet Oncol. 2007; 8: 475-487
        • Kupelian P.A.
        • Willoughby T.R.
        • Reddy C.
        • et al.
        Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience.
        Int J Radiat Oncol Biol Phys. 2007; 68: 1424-1430
        • Martin J.M.
        • Rosewall T.
        • Bayley A.
        • et al.
        Phase II trial of hypofractionated image-guided intensity modulated radiotherapy for localized prostate adenocarcinoma.
        Int J Radiat Oncol Biol Phys. 2007; 69: 1084-1089
        • Coote J.H.
        • Wylie J.P.
        • Cowan R.A.
        • et al.
        Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: Analysis of toxicity.
        Int J Radiat Oncol Biol Phys. 2009; 74: 1121-1127
      4. Lock M, Best L, Wong E, et al. A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer. Int J Radiat Oncol Biol Phys. In press

        • Zelefsky M.J.
        • Chan H.
        • Hunt M.
        • et al.
        Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.
        J Urol. 2006; 176: 1415-1419
        • Elliott S.P.
        • Meng M.V.
        • Elkin E.P.
        • et al.
        Incidence of urethral stricture after primary treatment for prostate cancer: Data from CaPSURE.
        J Urol. 2007; 178: 529-534
        • Katz M.S.
        • Efstathiou J.A.
        • D’Amico A.V.
        • et al.
        The “CaP Calculator”: An online decision support tool for clinically localized prostate cancer.
        BJU Int. 2010; 105: 1417-1422


      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.